Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sutro Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
STRO
Nasdaq
8731
https://www.sutrobio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sutro Biopharma Inc
Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
- Apr 2nd, 2024 7:13 pm
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
- Apr 2nd, 2024 10:18 am
Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
- Mar 27th, 2024 1:02 am
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
- Mar 25th, 2024 10:30 pm
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Mar 25th, 2024 8:30 pm
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
- Mar 21st, 2024 1:55 pm
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
- Feb 28th, 2024 9:36 am
Sutro Biopharma to Participate in Upcoming Investor Conferences
- Feb 6th, 2024 9:05 pm
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
- Jan 4th, 2024 9:05 pm
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
- Dec 18th, 2023 10:56 am
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
- Dec 14th, 2023 9:05 pm
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
- Dec 11th, 2023 9:05 pm
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
- Dec 4th, 2023 9:05 pm
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
- Nov 27th, 2023 9:00 pm
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
- Nov 21st, 2023 9:05 pm
Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates
- Nov 13th, 2023 10:12 pm
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
- Nov 13th, 2023 9:30 pm
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
- Nov 13th, 2023 1:32 pm
Sutro Biopharma (NASDAQ:STRO) shareholders are up 11% this past week, but still in the red over the last three years
- Nov 4th, 2023 2:26 pm
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
- Oct 22nd, 2023 8:25 am
Scroll